HealthCare Global EnterprisesNSE:HCG -2.25%79 ROE % is 0.65% as of Mar. 2026, which is 83% below its 10-year median of 3.86. GuruFocus rates NSE:HCG with a GF Score™ of 79/100 and a GF Value™ of ₹576.14 (Fairly Valued). The stock has 2 warning signs investors should review. Among 628 Healthcare Providers & Services companies, HealthCare Global Enterprises ranks worse than 64.81% on this metric.
The historical rank and industry rank for HealthCare Global Enterprises's ROE % or its related term are showing as below:
NSE:HCG'
s ROE % Range Over the Past 10 Years
Min: -35.88 Med: 3.86 Max: 6.86
Current: 1.3
During the past 12 years, HealthCare Global Enterprises's highest ROE % was 6.86%. The lowest was -35.88%. And the median was 3.86%.
NSE:HCG's ROE % is ranked worse than 64.81% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs NSE:HCG: 1.30
HealthCare Global Enterprises (NSE:HCG) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
HealthCare Global Enterprises ROE % Related Terms
HealthCare Global Enterprises ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, HealthCare Global Enterprises's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthCare Global Enterprises ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthCare Global Enterprises's ROE % distribution charts can be found below:
* The bar in red indicates where HealthCare Global Enterprises's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
HealthCare Global Enterprises (NSE:HCG) has a ROE % of 0.65% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on HealthCare Global Enterprises and its competitors. This is 83% below median its historical median of 3.86. According to the industry distribution chart, HealthCare Global Enterprises ranks #407 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 64.8%.
Is HealthCare Global Enterprises' ROE % too high?
HealthCare Global Enterprises' current ROE % of 0.65% is 83% below median its 10-year median of 3.86. The Healthcare Providers & Services industry median ROE % is 5.72. HealthCare Global Enterprises' value of 0.65% is 88.6% below this industry median. Based on the distribution chart, HealthCare Global Enterprises ranks #407 out of 628 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, HealthCare Global Enterprises has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HealthCare Global Enterprises' ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, HealthCare Global Enterprises ranks #407 out of 628 companies for ROE %. This places HealthCare Global Enterprises in the lower half of its industry. The industry median ROE % is 5.72. HealthCare Global Enterprises' value of 0.65% is 88.6% below this benchmark. While the company's 10-year median is 3.86 vs. the industry median of 5.72, HealthCare Global Enterprises has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HealthCare Global Enterprises's current ROE % of 0.65% is 88.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on HealthCare Global Enterprises and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HealthCare Global Enterprises's current ROE % is 0.65%, which is 83% below median its own 10-year median of 3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthCare Global Enterprises stock overvalued right now?
Based on GuruFocus' analysis, HealthCare Global Enterprises (NSE:HCG) is currently considered Fairly Valued. The stock's GF Value™ is ₹576.14, compared to a current price of ₹600.40 — trading 4.2% above its estimated fair value. The current ROE % is 0.65%, which is 83% below median its 10-year median of 3.86 and 88.6% below the Healthcare Providers & Services industry median of 5.72. HealthCare Global Enterprises' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For HealthCare Global Enterprises (NSE:HCG), the current ROE % is 0.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthCare Global Enterprises (NSE:HCG) Overvalued in 2026?
Based on GuruFocus' analysis, HealthCare Global Enterprises stock appears to be overvalued.
The current stock price of ₹600.40 is trading 4.2% above its estimated GF Value™ of ₹576.14.
GuruFocus considers HealthCare Global Enterprises to be Fairly Valued.
Key valuation signals for NSE:HCG:
ROE %: 0.65% (83% below median its 10-year median of 3.86)
GF Value™: ₹576.14 vs. price of ₹600.40 (4.2% above fair value)
Industry Position: 88.6% below the Healthcare Providers & Services median (#407 of 628)
No single metric tells the full story. See the NSE:HCG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthCare Global Enterprises Business Description
HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company's operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
79GF Score
Get the complete analysis for NSE:HCG
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HCG has been successfully added to your 
